Everything You Need to Know About Purine vs Pyrimidine Metabolism for Step 1

Purine and pyrimidine metabolism shows up on Step 1 in two big ways: (1) “what’s the pathway?” and (2) “which disease/drug blocks it and what happens clinically?” This guide is a high-yield, clinically anchored deep dive with First Aid-style associations and exam-ready differentiators.

---

Why This Topic Is High-Yield (Step 1 Mindset)

Expect questions that test your ability to:

• Differentiate purines vs pyrimidines (structure + products)
• Recognize rate-limiting enzymes and salvage pathways
• Predict consequences of enzyme deficiencies
• Connect drugs to blocked steps and adverse effects
• Identify classic vignettes: gout, SCID, Lesch-Nyhan, orotic aciduria, megaloblastic anemia

💡

First Aid cross-reference: Biochemistry → Nucleotide Structure/Metabolism; Pharmacology → Antimetabolites; Immunology → SCID.

---

Quick Definitions (Know Cold)

Purines

• Bases: Adenine (A) and Guanine (G)
• Structure: Two-ring structure (fused)
• Catabolism end product (humans): Uric acid
• Clinical hook: Hyperuricemia → gout, kidney stones, tumor lysis

Pyrimidines

• Bases: Cytosine (C), Thymine (T), Uracil (U)
• Structure: One-ring structure
• Catabolism: more water-soluble; no uric acid endpoint
• Clinical hook: Orotic aciduria, 5-FU, and dTMP synthesis

---

Core Concept: De Novo vs Salvage

De Novo Synthesis

• Builds nucleotides “from scratch”
• Energy intensive
• Purines: ring is built on ribose (PRPP)
• Pyrimidines: ring is built first, then attached to ribose

Salvage Pathway

• Recycles free bases
• Most important for purines
• Brain heavily relies on salvage → neurologic findings when impaired

💡

First Aid cross-reference: “Purine synthesis occurs on PRPP; pyrimidine ring synthesized then attached.”

---

Purine Metabolism (High-Yield Pathway + Regulation)

De Novo Purine Synthesis (A/G)

Key substrate: PRPP (from ribose-5-phosphate via HMP shunt)

Rate-limiting step: Glutamine-PRPP amidotransferase

• Activated by: PRPP
• Inhibited by: IMP, AMP, GMP (feedback inhibition)

Branch point: IMP → can become AMP or GMP

• AMP synthesis uses GTP
• GMP synthesis uses ATP
• (Classic “cross-energizing” regulation)

Pathophysiology tie-in

• Increased synthesis or decreased excretion → ↑ uric acid
• High cell turnover (chemo, leukemias) → tumor lysis syndrome → hyperuricemia

---

Purine Salvage (Where the Classic Diseases Live)

Key enzymes

• HGPRT: salvages Hypoxanthine and Guanine → IMP/GMP
• APRT: salvages Adenine → AMP

HY principle

If salvage is impaired → bases shunted to degradation → ↑ uric acid.

---

Purine Catabolism (Uric Acid = Endpoint)

Purines degrade → xanthine → uric acid
Xanthine oxidase catalyzes key steps.

Clinical hooks

• Gout (podagra, tophi, urate nephrolithiasis)
• Tumor lysis syndrome
• Lead poisoning (saturnine gout): impaired urate excretion

---

Pyrimidine Metabolism (High-Yield Pathway + Disease)

De Novo Pyrimidine Synthesis (C/U/T)

Key concept: Pyrimidine ring is made first, then attached to PRPP.

Rate-limiting enzyme: Carbamoyl phosphate synthetase II (CPS II) (cytosol)

• Uses glutamine
• Distinguish from CPS I (mitochondria, urea cycle, uses NH3)

Important intermediate: Orotic acid

• Orotic acid + PRPP → OMP → UMP (then → UDP/UTP → CTP)

Thymidine (dTMP) synthesis (board favorite)

• dUMP → dTMP via thymidylate synthase
• Requires N5,N10-methylene-THF
• Dihydrofolate reductase (DHFR) regenerates THF

💡

First Aid cross-reference: Folate trap, megaloblastic anemia, 5-FU, methotrexate, TMP-SMX.

---

High-Yield Disorders: Presentation → Diagnosis → Treatment

1) Lesch-Nyhan Syndrome (Purine Salvage Defect)

Defect: HGPRT deficiency (X-linked recessive)
Pathophysiology: ↓ purine salvage → ↑ de novo synthesis + ↑ uric acid

Clinical presentation (classic vignette)

• Self-injury (biting fingers/lips), aggression
• Dystonia/choreoathetosis
• Hyperuricemia → gout, nephrolithiasis
• Orange “sand” crystals in diaper (urate)

Diagnosis

• Elevated uric acid
• Genetic testing / enzyme assay

Treatment

• Allopurinol or febuxostat (reduce uric acid production)
• Supportive/neurobehavioral management
• Note: lowering uric acid does not fix neurologic symptoms

HY association: “HGPRT = HGPRT → Gout + self-mutilation + neuro symptoms.”

---

2) Adenosine Deaminase (ADA) Deficiency (Purine Catabolism → Immunology)

Defect: ADA deficiency → buildup of deoxyadenosine → ↑ dATP
Mechanism: dATP inhibits ribonucleotide reductase → ↓ DNA synthesis → lymphotoxic

Clinical presentation

• SCID: severe recurrent infections, chronic diarrhea, failure to thrive
• Absent thymic shadow
• Low T, B, NK function (classically combined immunodeficiency)

Diagnosis

• Newborn screen (TREC low), lymphopenia, enzyme assay/genetics

Treatment

• Hematopoietic stem cell transplant
• PEG-ADA enzyme replacement (in some settings)
• Gene therapy in select cases

💡

First Aid cross-reference: Immunology → SCID; Biochem → ADA.

---

3) Xanthine Oxidase & Gout (Purine Catabolism)

Pathophysiology

Hyperuricemia from:

• Overproduction (tumor lysis, Lesch-Nyhan)
• Underexcretion (renal disease, thiazides, lead)

Clinical presentation

• Acute monoarthritis (often 1st MTP)
• Tophi, uric acid stones

Diagnosis

• Joint aspiration: negatively birefringent, needle-shaped crystals

Treatment

Acute flare:

• NSAIDs (e.g., indomethacin), colchicine, glucocorticoids

Chronic urate lowering:

• Allopurinol/febuxostat (xanthine oxidase inhibitors)
• Probenecid (uricosuric; not ideal in kidney stones)

HY drug toxicity association:

• Allopurinol: rash, hypersensitivity; ↑ azathioprine/6-MP toxicity (XO normally metabolizes them)

---

4) Orotic Aciduria (Pyrimidine Synthesis Defect)

Defect: UMP synthase deficiency (orotate phosphoribosyltransferase + OMP decarboxylase activities)
Pathophysiology: Can’t convert orotic acid → UMP → ↓ pyrimidines → impaired DNA synthesis

Clinical presentation

• Megaloblastic anemia (refractory to B12/folate)
• Failure to thrive, developmental delay
• Increased orotic acid in urine
• No hyperammonemia (key differentiator)

Diagnosis

• Elevated urinary orotic acid
• Normal ammonia (helps separate from OTC deficiency)

Treatment

• Uridine supplementation (bypasses the block → provides UMP)

💡

First Aid cross-reference: Biochem → “orotic aciduria vs OTC deficiency.”

---

Must-Know Differential: Orotic Aciduria vs OTC Deficiency

Both can have ↑ orotic acid, but Step 1 loves the separator:

---

High-Yield Drugs That Hit Nucleotide Metabolism (Step 1 Favorite)

Inhibit DNA synthesis (antimetabolites)

• Methotrexate: inhibits DHFR → ↓ THF → ↓ dTMP
  • Toxicity: mucositis, myelosuppression; rescue with leucovorin
• Trimethoprim (TMP): inhibits bacterial DHFR
• Pyrimethamine: inhibits protozoal DHFR
• 5-Fluorouracil (5-FU) (also capecitabine): inhibits thymidylate synthase via FdUMP
  • Major toxicity: myelosuppression, mucositis/diarrhea
• Hydroxyurea: inhibits ribonucleotide reductase (↓ deoxyribonucleotides)

Purine analogs (chemo/immunosuppressants)

• 6-mercaptopurine (6-MP) / azathioprine: inhibit de novo purine synthesis
  • Metabolized by xanthine oxidase → allopurinol/febuxostat increases toxicity
• Mycophenolate mofetil: inhibits IMP dehydrogenase → ↓ GMP (particularly affects lymphocytes)

💡

First Aid cross-reference: Pharm → Antimetabolites; Biochem → thymidylate synthase/DHFR.

---

Exam-Proof “Purine vs Pyrimidine” Differentiators

Structural & naming cues

• Purines (A,G) = PURe As Gold
• Pyrimidines (C,T,U) = CUT the PY

Synthesis logic

• Purine: build ring on PRPP → IMP intermediate
• Pyrimidine: build ring first (CPS II) → orotic acid → attach to PRPP

Clinical endpoints

• Purines → uric acid → gout/kidney stones
• Pyrimidines → no uric acid disease equivalents; think orotic aciduria and dTMP synthesis

---

Ultra-High-Yield Rapid Review (What to Memorize)

• Purines: A/G; two rings; uric acid end product
• Pyrimidines: C/T/U; one ring; orotic acid intermediate
• Purine rate-limiting: glutamine-PRPP amidotransferase
• Pyrimidine rate-limiting: CPS II (cytosol)
• HGPRT deficiency: Lesch-Nyhan (self-injury + hyperuricemia)
• ADA deficiency: SCID (↓ DNA synthesis via ↑ dATP inhibiting RNR)
• UMP synthase deficiency: orotic aciduria (megaloblastic anemia, no hyperammonemia)
• dTMP synthesis: thymidylate synthase + folate cycle (targets: 5-FU, MTX)
• Allopurinol/febuxostat: inhibit xanthine oxidase; interact with 6-MP/azathioprine

---

First Aid Cross-References (Where This Lives)

Look in these First Aid (FA) buckets while you annotate:

• Biochemistry: Nucleotide structure, de novo synthesis, salvage pathways, uric acid metabolism
• Immunology: SCID (ADA deficiency)
• Pharmacology: Antimetabolites (MTX, 5-FU, 6-MP/azathioprine, hydroxyurea), gout drugs (allopurinol, colchicine)